Miki Takemura, n/a

Director, Head of Infectious Diseases 5, Laboratory for Drug Discovery and Disease Research
Shionogi & Co., Ltd

Disclosure: Shionogi & Co., Ltd. (Employee)

Miki Takemura, MS, Director, Head of Infectious Diseases 5, Laboratory for Drug Discovery and Disease Research, SHIONOGI & CO., LTD.
I have been engaged in antibacterial drug research for 14 years at SHIONOGI & CO., LTD., located in Osaka, Japan.
In recent years, I have been in charge of non-clinical pharmacology of a novel siderophore cephalosporin, cefierocol.

Poster(s):

1252 - In Vitro Activity of Cefiderocol Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria Collected in North America and Europe Between 2014 and 2017: SIDERO-WT-2014–2016 Studies
1266 - Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies
1269 - Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
1452 - Molecular Profile of β-Lactamase Genes and Siderophore-Dependent Iron Transporter Genes of Cefiderocol High MIC Isolates from SIDERO-WT Studies
1455 - Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies
1626 - Synergistic Effect of Cefiderocol with Other Antibiotics Against PER-Producing Acinetobacter baumannii Isolates from the Multinational SIDERO-WT Studies